A Phase 1/2 interventional study of SonoVue and Focused Ultrasound in Colorectal Neoplasms and Breast Neoplasms, sponsored by St. Olavs Hospital. Completed at 1 site in Norway. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-01-19.
Sponsored by St. Olavs Hospital · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Colorectal Neoplasms with a site in Norway — 19 open to participants now, 35 under way, 6 of them phase 3. Colorectal Neoplasms · Norway.
Among the 82 studies in Colorectal Neoplasms with a site in Norway, this one is the 63rd largest by enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2018, is one of 9 in phase 1/2, and was the 48th registered.
6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.
Browse Colorectal Neoplasms studies →19 of the 82 studies in Colorectal Neoplasms with a site in Norway are open now. Recruiting first, the newest first:
University of Edinburgh · Sites in Norway, United Kingdom
Ages 18+
Incyte Corporation · Sites in Norway, United States, Argentina and 19 more countries
Ages 18+
Sorlandet Hospital HF · Sites in Norway
Ages 40–75
Oncosyne AS · Sites in Norway
Ages 18+
GlaxoSmithKline · Sites in Norway, United States, Australia and 16 more countries
Ages 18+
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 22 · Phase 3 19
First in 1983; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 76 across 4,810 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 172 across the 68 interventional studies, 427 across the 12 observational. Of the 39 that completed or were terminated, 12 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 82 have an industry lead sponsor. The 10 most frequent:
St. Olavs Hospital is the lead sponsor of 171 studies on the registry; 29 are open to participants now.
St. Olavs Hospital has 3 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
5 of the studies in Colorectal Neoplasms with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04726800Anna MartlingCirculating Tumour DNA (ctDNA) as a Prognostic and Predictive Marker in Colorectal Cancer - a Pilot Study | 2026-12 |
| NCT06333392Vestre Viken Hospital TrustTotal Underwater Colonoscopy (TUC) for Improved Colorectal Cancer Screening: A Randomized Controlled Trial | 2026-12 |
| NCT07255066University of EdinburghOptimizing Patient Treatment With EPA-enriched Nutrition, a Randomised Control Trial | 2027-01 |
| NCT03494946Oslo University HospitalLiver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer | 2027-01 |
| NCT05838768Novartis PharmaceuticalsStudy of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 82 studies in Colorectal Neoplasms with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this clinical trial is to investigate whether the therapeutic response of chemotherapy can be improved by focused ultrasound and microbubbles. Patients with liver metastases from breast cancer and colorectal cancer will be included. Computer Tomography (CT) will be performed as a baseline scan before treatment start. Two metastases in each patients liver will be preselected and randomized to either "target lesion" to be treated or "control lesion" to serve as internal control. The patients will receive conventional treatment with chemotherapy according to national guidelines. After intravenous chemotherapy infusion the patients will receive the experimental treatment. The target lesion will get focused ultrasound (FUS). Simultaneously repeated bolus-doses of microbubbles will be administered intravenously. The investigators will measure the difference in response between FUS- treated and -untreated lesions on the post-treatment CT scan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm will receive experimental treatment of focused ultrasound. In addition this arm will receive treatment with microbubbles intravenously and conventional chemotherapy for breast cancer.
Drug: SonoVue · Procedure: Focused Ultrasound
This arm will only receive treatment with conventional chemotherapy for breastcancer and microbubbles intravenously.
Drug: SonoVue
This arm will receive experimental treatment of focused ultrasound. In addition this arm will receive treatment with microbubbles intravenously and conventional chemotherapy for colorectal cancer.
Drug: SonoVue · Procedure: Focused Ultrasound
This arm will only receive treatment with conventional chemotherapy for colorectal cancer and microbubbles intravenously.
Drug: SonoVue
consists of microbubbles containing sulfur hexafluoride stabilized by phospholipids. Bolus doses à 1,0ml administered every 3.5 minutes , repeated 9 times. Total duration of treatment: 31,5 minutes. This treatment will be repeated maximally 4 times at 2 or 3 week intervals, depending on the patient's diagonse and treatment protocol.
ultrasound pulses will be generated by a clinically approved ultrasound skanner and probe.
difference in measured response between treated and untreated lesions
Response is measured in change in size of the treated metastases.
Time frame: From baseline examination CT to response evaluation CT: 10-12 weeks
Occurrence of adverse effects
questionnaire 'Common toxicity criteria'
Time frame: 8 weeks
Plan to share: Undecided — Yes.Individual participant data that underlie the results reported in this article, after deidentification(text, tables, figures, and appendices). Protocol can be shared beginning 3 months and ending 5 years following article publication. Interested researchers who provide a reasonable, sound proposal are encouraged to direct this to the first author.
No publications or documents are linked to this record.
Ran from Nov 2018 to primary completion in Dec 2022, 49 months.
Of 102 non-industry phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 106. This study's 49 months is below that.
Counting every sponsor, half of 261 studies reached it within 59 months; a quarter within 36 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.